Amgen's Nplate prompts NICE turnaround on GSK's Revolade
This article was originally published in Scrip
Executive Summary
Two years after it initially said no, NICE, the health technology appraisal institute for England and Wales, looks set to recommend GlaxoSmithKline's thrombopoietin receptor agonist Revolade (eltrombopag) for chronic immune (idiopathic) thrombocytopenic purpura (ITP). The institute decided to review the guidance after GSK offered a discount on the drug and after the institute recommended a key comparator, Amgen's Nplate, explained GSK.